Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
about
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study.Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction.Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine.Psychosis and seizure disorder: challenges in diagnosis and treatment.Seizure associated with clozapine: incidence, etiology, and management.Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline.Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.Clozapine administration in clinical practice: once-daily versus divided dosing.Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance.The significance of sampling time in therapeutic drug monitoring of clozapine.
P2860
Q30382281-650BDEF2-BD07-45E6-A798-8F6288484A0CQ35111188-15A0EDFD-1606-4AE9-80F6-C990AAC81A79Q35754726-5A8648D9-065A-43E9-A4A4-0A7E23F16DE0Q36754155-1A43E70C-53CC-4EFD-8B0C-C6E5F260187AQ37410806-15E1C84D-1F36-4AD0-B330-EBA6FA61B682Q38162870-6E33438C-54DC-42E1-A78D-E9705ACCC4E8Q38252369-273956C4-7DD6-413B-B4B6-D97CE2F29D08Q38299304-BF82CDDA-2619-4F41-BCF0-C3DFDCED1309Q38578316-ACB22E89-E38C-4C3E-A6C8-1AD6BE1523E3Q38840211-B488BA8D-0CBB-4730-BF56-A8699D93C4FEQ39117848-2D2F67AA-3EC1-4075-A0C5-266D6211F583Q39763748-85163F87-60FE-4BC3-8509-BEE0BF9B3F66Q47100336-A271FD0B-D8DB-4C8E-BF3B-0C4C5623C82FQ51026132-117663D2-1392-47B0-89A3-B761406AF3B2
P2860
Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Clozapine and therapeutic drug ...... idence for an upper threshold?
@en
type
label
Clozapine and therapeutic drug ...... idence for an upper threshold?
@en
prefLabel
Clozapine and therapeutic drug ...... idence for an upper threshold?
@en
P2860
P50
P1433
P1476
Clozapine and therapeutic drug ...... idence for an upper threshold?
@en
P2093
Larissa Ferguson
Valerie Powell
P2860
P2888
P304
P356
10.1007/S00213-012-2922-7
P577
2012-11-22T00:00:00Z
P6179
1035795609